Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
PG Richardson, JF San Miguel, P Moreau… - Blood cancer …, 2018 - nature.com
Substantial improvements in survival have been seen in multiple myeloma (MM) over recent
years, associated with the introduction and widespread use of multiple novel agents and …
years, associated with the introduction and widespread use of multiple novel agents and …
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
G Thanarajasingam, LM Minasian, F Baron… - The Lancet …, 2018 - thelancet.com
Tremendous progress in treatment and outcomes has been achieved across the whole
range of haematological malignancies in the past two decades. Although cure rates for …
range of haematological malignancies in the past two decades. Although cure rates for …
Patient-reported outcomes among multiple myeloma patients treated with standard of care idecabtagene vicleucel
Simple Summary In clinical trials, patients treated with idecabtagene vicleucel (ide-cel)
chimeric antigen receptor T-cell therapy (CAR T) have reported meaningful improvements in …
chimeric antigen receptor T-cell therapy (CAR T) have reported meaningful improvements in …
[HTML][HTML] Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France
N Despiégel, C Touboul, A Flinois, G Saba… - … Myeloma and Leukemia, 2019 - Elsevier
Introduction New therapies for multiple myeloma (MM) have improved life expectancy, but
health-related quality of life (HRQoL) data from patients with MM in the real-world setting are …
health-related quality of life (HRQoL) data from patients with MM in the real-world setting are …
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA …
F Efficace, G Gaidano, MT Petrucci… - The Lancet Healthy …, 2022 - thelancet.com
Background The clinical management of patients with relapsed or refractory multiple
myeloma is challenging and there is a paucity of tools to help clinicians make more informed …
myeloma is challenging and there is a paucity of tools to help clinicians make more informed …
[HTML][HTML] Health-related quality of life after autologous stem cell transplantation for multiple myeloma
R Chakraborty, BK Hamilton, SK Hashmi… - Biology of Blood and …, 2018 - Elsevier
Autologous stem cell transplantation (ASCT) is an integral part of the frontline therapy in
eligible multiple myeloma (MM) patients. The impact of ASCT on health-related quality of life …
eligible multiple myeloma (MM) patients. The impact of ASCT on health-related quality of life …
Strategies to improve patient-reported outcome completion rates in longitudinal studies
LK Nielsen, M King, S Möller, M Jarden… - Quality of Life …, 2020 - Springer
Purpose The quality of patient-reported outcome (PRO) data can be compromised by non-
response (NR) to scheduled questionnaires, particularly if reasons for NR are related to …
response (NR) to scheduled questionnaires, particularly if reasons for NR are related to …
How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review
MR LeBlanc, R Hirschey, A Leak Bryant… - Quality of Life …, 2020 - Springer
Purpose Patients with relapsed and/or refractory multiple myeloma (RRMM) are living longer
due in part to changing treatment patterns. It is important to understand how changing …
due in part to changing treatment patterns. It is important to understand how changing …
Treatment and disease‐related complications in multiple myeloma: implications for survivorship
R Chakraborty, NS Majhail - American journal of hematology, 2020 - Wiley Online Library
New treatments have transformed multiple myeloma into a chronic disease. Hence, optimal
management of treatment and disease‐related complications remains a critical component …
management of treatment and disease‐related complications remains a critical component …
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and …
Patients with relapsed/refractory multiple myeloma (RRMM) need proven subsequent
therapies after early-line lenalidomide treatment failure. The phase 2 MM-014 trial …
therapies after early-line lenalidomide treatment failure. The phase 2 MM-014 trial …